When a small molecule development programme involves a high-potency Active Pharmaceutical Ingredient (HPAPI), selecting the right Contract Development and Manufacturing Organisation (CDMO) becomes a decision with direct consequences for operator safety, product quality and regulatory compliance. Containment capability is not […]
Contents Aseptic Fill-Finish for Commercial Pre-Filled Syringe Programmes Supporting Sterile Injectable Formats Manufacturing Site: Maisons-Alfort, France Regulatory Certification and Global Compliance Supply Reliability for Global Programmes Evaluating a European CDMO for Pre-Filled Syringes Discuss Your Programme with Adragos Pharma Pre-Filled […]
Selecting a Contract Development and Manufacturing Organisation for High-Potency Active Pharmaceutical Ingredient small molecule programmes requires a structured, evidence-based evaluation. The critical criteria are: validated Occupational Exposure Band 5 containment, Good Manufacturing Practice certification that explicitly covers the high-potency suite, […]
Pharmaceutical and biotech companies selecting sterile injectable contract development and manufacturing organisation (CDMO) services in Europe must evaluate partners across seven critical dimensions: programme-fit and technical capability, regulatory standing and Good Manufacturing Practice (GMP) certifications, Chemistry, Manufacturing and Controls (CMC) […]
A Strategic Guide to Navigating Early-Stage Fill-Finish for Biologics Optimising early-stage fill-finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into […]
For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables […]
Get notified on our latest news.
